Curaleaf Holdings (CURLF) EBT Margin (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly EBT Margin of 8.83% for Q1 2026, down 348.0% year-on-year from 3.56% in Q1 2025, and down 70.51% on a QoQ basis from 5.18% in Q4 2025.
Curaleaf Holdings (CURLF) EBT Margin (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported EBT Margin for 8 consecutive years, with 8.83% the latest figure, recorded in Q1 2026.
- Quarterly EBT Margin fell 348.0% year-over-year to 8.83% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.93% (up 215.0% YoY) and the FY2025 annual result came in at 6.17%, up 233.0% from the prior year.
- EBT Margin declined to 8.83% in Q1 2026 per CURLF's latest filing, from 5.18% in the prior quarter.
- Over the last five years, EBT Margin for CURLF reached as high as 9.79% in Q2 2022 and fell as low as 17559062.64% in Q4 2023.
- A 5-year average of 1032894.18% and a median of 5.35% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin plunged 1755899170 bps — and 2024, when it surged 1755904002 bps.
- Year by year, EBT Margin stood at 70.94% in 2022, then slumped by 24751442 bps to 17559062.64% in 2023, then surged by 100 bps to 22.62% in 2024, then surged by 77 bps to 5.18% in 2025, then sank by 71 bps to 8.83% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 8.83%, 5.18%, and 7.59% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | -8.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.83% |
| Dec 31, 2025 | -5.18% |
| Sep 30, 2025 | -7.59% |
| Jun 30, 2025 | -6.11% |
| Mar 31, 2025 | -5.35% |
| Dec 31, 2024 | -22.62% |
| Sep 30, 2024 | -3.56% |
| Jun 30, 2024 | -5.01% |
| Mar 31, 2024 | -3.39% |
| Dec 31, 2023 | -17,559,062.64% |
| Sep 30, 2023 | -10.79% |
| Jun 30, 2023 | -7.34% |
| Mar 31, 2023 | -0.95% |
| Dec 31, 2022 | -70.94% |
| Sep 30, 2022 | 2.63% |
| Jun 30, 2022 | 9.79% |
| Mar 31, 2022 | 6.86% |
| Dec 31, 2021 | -13.11% |
| Sep 30, 2021 | 0.84% |
| Jun 30, 2021 | 11.06% |